Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics

European Journal of Human Genetics volume 32, pages 278–285 (2024)Cite this article

Subjects

Abstract

The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate pharmacogenetics implementation in clinical practice by developing evidence-based guidelines to optimize pharmacotherapy. A guideline describing the gene-drug interaction between the genes CYP2D6, CYP3A4 and CYP1A2 and antipsychotics is presented here. The DPWG identified gene-drug interactions that require therapy adjustments when respective genotype is known for CYP2D6 with aripiprazole, brexpiprazole, haloperidol, pimozide, risperidone and zuclopenthixol, and for CYP3A4 with quetiapine. Evidence-based dose recommendations were obtained based on a systematic review of published literature. Reduction of the normal dose is recommended for aripiprazole, brexpiprazole, haloperidol, pimozide, risperidone and zuclopenthixol for CYP2D6-predicted PMs, and for pimozide and zuclopenthixol also for CYP2D6 IMs. For CYP2D6 UMs, a dose increase or an alternative drug is recommended for haloperidol and an alternative drug or titration of the dose for risperidone. In addition, in case of no or limited clinical effect, a dose increase is recommended for zuclopenthixol for CYP2D6 UMs. Even though evidence is limited, the DPWG recommends choosing an alternative drug to treat symptoms of depression or a dose reduction for other indications for quetiapine and CYP3A4 PMs. No therapy adjustments are recommended for the other CYP2D6 and CYP3A4 predicted phenotypes. In addition, no action is required for the gene-drug combinations CYP2D6 and clozapine, flupentixol, olanzapine or quetiapine and also not for CYP1A2 and clozapine or olanzapine. For identified gene-drug interactions requiring therapy adjustments, genotyping of CYP2D6 or CYP3A4 prior to treatment should not be considered for all patients, but on an individual patient basis only.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Data availability

All data and material are either included in the Supplementary information or publicly available (i.e., the published articles, PubMed). The guidelines and background information are available on the website of the Royal Dutch Pharmacists Association (KNMP) (Pharmacogenetic Recommendation Text. Available from: https://www.knmp.nl/). The guidelines and background information will also be available on PharmGKB.org.

References

  1. Swen JJ, Huizinga TW, Gelderblom H, de Vries EGE, Assendelft WJJ, Kirchheiner J, et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med. 2007;4:e209.

    Article  PubMed  PubMed Central  Google Scholar 

  2. van Westrhenen R, Aitchison KJ, Ingelman-Sundberg M, Jukić MM. Pharmacogenomics of antidepressant and antipsychotic treatment: How far have we got and where are we going? Front Psychiatry. 2020;11:94.

    Article  PubMed  PubMed Central  Google Scholar 

  3. van Westrhenen R, Ingelman-Sundberg M. Editorial: from trial and error to individualised pharmacogenomics-based pharmacotherapy in psychiatry. Front Pharmacol. 2021;12:725565.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Swen JJ, Wilting I, de Goede AL, Grandia L, Mulder H, Touw DJ, et al. Pharmacogenetics: from bench to byte. Clin Pharm Ther. 2008;83:781–7.

    Article  CAS  Google Scholar 

  5. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte - an update of guidelines. Clin Pharm Ther. 2011;89:662–73.

    Article  CAS  Google Scholar 

  6. Marcath LA, Pasternak AL, Hertz DL. Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications. Pharmacogenomics J. 2019;19:501–15.

    Article  CAS  PubMed  Google Scholar 

  7. Guchelaar H-J. Pharmacogenomics, a novel section in the European Journal of Human Genetics. Eur J Hum Genet. 2018;26:1399–400.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Matic M, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk A-M, Houwink EJF, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). Eur J Hum Genet. 2021;30:1105–13.

  9. Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, et al. Standardizing CYP2D6 genotype to phenotype translation: Consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. 2020;13:116–24.

    Article  PubMed  Google Scholar 

  10. CYP3A4 cytochrome P450 family 3 subfamily A member 4 [Homo sapiens (human)] [Internet]. National Center for Biotechnology Information. [cited 2021 Nov 9]. Available from: https://www.ncbi.nlm.nih.gov/gene/1576.

  11. CYP3A4 cytochrome P450 family 3 subfamily A member 4 [Internet]. Genome Aggregation Database. [cited 2021 Nov 9]. Available from: https://gnomad.broadinstitute.org/gene/ENSG00000160868?dataset=gnomad_r2_1.

  12. CYP3A4 [Internet]. Pharmacogene Variation Consortium. [cited 2021 Nov 9]. Available from: https://www.pharmvar.org/gene/CYP3A4.

  13. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011;11:274–86.

    Article  PubMed  Google Scholar 

  14. Annotation of RNPGx Guideline for tacrolimus and CYP3A4, CYP3A5 [Internet]. PharmGKB. [cited 2022 Dec 14]. Available from: https://www.pharmgkb.org/chemical/PA451578/guidelineAnnotation/PA166202481.

  15. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di Rienzo A. CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet. 2004;75:1059–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, van Schaik RHN. The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet Genomics. 2012;22:373–80.

    Article  CAS  PubMed  Google Scholar 

  17. Elens L, Becker ML, Haufroid V, Hofman A, Visser LE, Uitterlinden AG, et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet Genomics. 2011;21:861–6.

    Article  CAS  PubMed  Google Scholar 

  18. van der Weide K, van der Weide J. The influence of the CYP3A4*22 polymorphism on serum concentration of quetiapine in psychiatric patients. J Clin Psychopharmacol. 2014;34:256–60.

    Article  PubMed  ADS  Google Scholar 

  19. Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011;57:1574–83.

    Article  CAS  PubMed  Google Scholar 

  20. Apellániz-Ruiz M, Lee M-Y, Sánchez-Barroso L, Gutiérrez-Gutiérrez G, Calvo I, García-Estévez L, et al. Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy. Clin cancer Res. 2015;21:322–8.

    Article  PubMed  Google Scholar 

  21. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics. 2002;12:121–32.

    Article  CAS  PubMed  Google Scholar 

  22. Nakajima Y, Yoshitani T, Fukushima-Uesaka H, Saito Y, Kaniwa N, Kurose K, et al. Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clin Pharm Ther. 2006;80:179–91.

    Article  CAS  Google Scholar 

  23. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharm Ther. 2017;102:688–700.

    Article  CAS  Google Scholar 

  24. CYP1A2 cytochrome P450 family 1 subfamily A member 2 [Homo sapiens (human)] [Internet]. National Center for Biotechnology Information. [cited 2021 Nov 9]. Available from: https://www.ncbi.nlm.nih.gov/gene/1544.

  25. CYP1A2 cytochrome P450 family 1 subfamily A member 2 [Internet]. Genome Aggregation Database. [cited 2021 Nov 9]. Available from: https://gnomad.broadinstitute.org/gene/ENSG00000140505?dataset=gnomad_r2_1.

  26. CYP1A2 allele nomenclature [Internet]. Pharmacogene Variation Consortium. [cited 2021 Nov 9]. Available from: https://www.pharmvar.org/gene/CYP1A2.

  27. Nordmark A, Lundgren S, Ask B, Granath F, Rane A. The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women. Br J Clin Pharm. 2002;54:504–10.

    Article  CAS  Google Scholar 

  28. Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L, et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharm. 2003;64:659–69.

    Article  CAS  Google Scholar 

  29. Takata K, Saruwatari J, Nakada N, Nakagawa M, Fukuda K, Tanaka F, et al. Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy. Eur J Clin Pharm. 2006;62:23–8.

    Article  CAS  Google Scholar 

  30. McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol. 2012;8:371–82.

    Article  CAS  PubMed  Google Scholar 

  31. Soyama A, Saito Y, Hanioka N, Maekawa K, Komamura K, Kamakura S, et al. Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab Pharmacokinet. 2005;20:24–33.

    Article  CAS  PubMed  Google Scholar 

  32. Kootstra-Ros JE, Smallegoor W, van der Weide J. The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients. Ann Clin Biochem. 2005;42:216–9.

    Article  CAS  PubMed  Google Scholar 

  33. Looman NMG, Matic M, Mulder H, Van Hulst R, Van Schaik RHN, Bruggeman R. Associatie van genetische variatie in CYP1A2 en UCT1A4 met metabole stoornissen bij gebruikers van clozapine en olanzapine [Association of genetic variation in CYP1A2 and UGT1A4 with metabolic disorders in users of clozapine and olanzapine]. Pharm Weekbl. 2013;7:163–6.

    Google Scholar 

  34. Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn CF, Whaley R, et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharm Ther. 2021;110:563–72.

    Article  Google Scholar 

  35. Pirmohamed M, Hughes DA. Pharmacogenetic tests: the need for a level playing field. Nat Rev Drug Disco. 2013;12:3–4.

    Article  CAS  Google Scholar 

  36. Swen JJ, Nijenhuis M, van Rhenen M, de Boer-Veger NJ, Buunk A-M, Houwink EJF, et al. Pharmacogenetic information in clinical guidelines: The European perspective. Clin Pharm Ther. 2018;103:795–801.

    Article  Google Scholar 

  37. Prioritization of CPIC guidelines [Internet]. Clinical Pharmacogenetics Implementation Consortium. [cited 2021 Nov 9]. Available from: https://cpicpgx.org/prioritization-of-cpic-guidelines/.

  38. U.S. Food and Drug Association (FDA). Table of pharmacogenetic associations [Internet]. [cited 2022 Mar 1]. Available from: https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations.

Download references

Acknowledgements

We want to thank Leonora Grandia and Anna de Goede for performing the systematic reviews in 2005 and 2006, Mandy van Rhenen for performing the 2013 update of clozapine and CYP2D6 and the 2014 updates of pimozide and risperidone and CYP2D6, and Yasmina Laouti for performing the 2020 updates of clozapine, haloperidol and zuclopenthixol and CYP2D6.

Funding

This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 668353. The DPWG received funding from the Royal Dutch Pharmacists Association.

Author information

Authors and Affiliations

  1. Department of Clinical Chemistry, St Jansdal Hospital, Harderwijk, the Netherlands

    Lianne Beunk & Jan van der Weide

  2. Royal Dutch Pharmacists Association (KNMP), The Hague, the Netherlands

    Marga Nijenhuis & Bianca Soree

  3. Pharmacy Boterdiep, Groningen, the Netherlands

    Nienke J. de Boer-Veger

  4. Pharmacy De Katwijkse Apotheek, Katwijk, the Netherlands

    Anne-Marie Buunk

  5. Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands

    Henk Jan Guchelaar & Jesse J. Swen

  6. Department of Public Health and Primary Care (PHEG), Leiden University Medical Center, Leiden, the Netherlands

    Elisa J. F. Houwink

  7. National eHealth Living Lab (NELL), Leiden, the Netherlands

    Elisa J. F. Houwink

  8. Department of Clinical Pharmacy, Wilhelmina Hospital, Assen, the Netherlands

    Arne Risselada

  9. Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands

    Gerard A. P. J. M. Rongen

  10. Department of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands

    Gerard A. P. J. M. Rongen

  11. Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands

    Ron H. N. van Schaik

  12. Department of Pharmaceutical Analysis, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands

    Daan Touw

  13. Department of Clinical Pharmacy & Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

    Daan Touw

  14. Department of Psychiatry, Parnassia Group, Amsterdam, the Netherlands

    Roos van Westrhenen

  15. Department of Psychiatry and Neuropsychology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands

    Roos van Westrhenen

  16. Institute of Psychiatry, Psychology&Neuroscience (IoPPN), King’s College London, London, UK

    Roos van Westrhenen

  17. Department of Clinical Pharmacy, Division Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands

    Vera H. M. Deneer

  18. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands

    Vera H. M. Deneer

Authors
  1. Lianne Beunk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marga Nijenhuis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bianca Soree
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nienke J. de Boer-Veger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anne-Marie Buunk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Henk Jan Guchelaar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Elisa J. F. Houwink
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Arne Risselada
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Gerard A. P. J. M. Rongen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ron H. N. van Schaik
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jesse J. Swen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Daan Touw
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Roos van Westrhenen
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Vera H. M. Deneer
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Jan van der Weide
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LB drafted the manuscript and contributed to interpretation of results. JvW supervised drafting of the manuscript and contributed to conceiving the work and interpretation of the results. MN contributed to conceiving the work and interpretation of the results, and performed the data extraction. BS drafted and published English versions of clinical decision support texts. NBV, AB, HG, EH, AR, GR, RvS, JS, DT, RvW, and VD contributed to conceiving the work and interpretation of the results. In addition, all authors revised the manuscript and approved the final version as well as agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Corresponding author

Correspondence to Marga Nijenhuis.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethical approval

This research involves a literature study and no human subjects, human material, or human data. Therefore, no approval by an ethics committee was needed.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beunk, L., Nijenhuis, M., Soree, B. et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics. Eur J Hum Genet 32, 278–285 (2024). https://doi.org/10.1038/s41431-023-01347-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41431-023-01347-3

This article is cited by

Search

Advanced search

Quick links